|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||251.90 - 255.73|
|52-week range||251.90 - 255.73|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IRVING, Texas, December 29, 2021--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2022 financial results after market close on Wednesday, February 2, 2022. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
IRVING, Texas, December 20, 2021--McKesson Corporation (NYSE: MCK) today announced that it has entered into an agreement to sell its Austrian business to Quadrifolia Management GmbH ("Quadrifolia"). The transaction includes the sale of McKesson Austria’s Herba Chemosan Apotheker-AG, together with Sanova Pharma GesmbH. The transaction is expected to close in fiscal 2022, subject to customary closing conditions, including receipt of required regulatory approvals.
IRVING, Texas, December 08, 2021--McKesson Corporation (NYSE: MCK) today will host an Investor Day beginning at 1:00 p.m. ET, where executive leadership will provide an overview of the company’s progress towards its goal of delivering sustainable growth and details around the company’s long-term financial outlook.